BIORESTORATIVE THERAPIES INC (BRTX) Stock Fundamental Analysis
USA - NASDAQ:BRTX - US0906556065 - Common Stock
1.38 USD
+0.01 (+0.73%)
1.5382 USD
+0.16 (+11.46%)
We assign a fundamental rating of 4 out of 10 to BRTX. BRTX was compared to 531 industry peers in the Biotechnology industry. While BRTX seems to be doing ok healthwise, there are quite some concerns on its profitability. BRTX shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year BRTX has reported negative net income.
BRTX had a negative operating cash flow in the past year.
In the past 5 years BRTX always reported negative net income.
In the past 5 years BRTX always reported negative operating cash flow.
1.2 Ratios
BRTX's Return On Assets of -125.92% is on the low side compared to the rest of the industry. BRTX is outperformed by 81.73% of its industry peers.
BRTX's Return On Equity of -221.32% is on the low side compared to the rest of the industry. BRTX is outperformed by 69.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -125.92% | ||
| ROE | -221.32% | ||
| ROIC | N/A |
ROA(3y)-89.42%
ROA(5y)-144.93%
ROE(3y)-108.73%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 94.53%, BRTX belongs to the top of the industry, outperforming 94.35% of the companies in the same industry.
BRTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 94.53% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
BRTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
BRTX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, BRTX has more shares outstanding
BRTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -29.41, we must say that BRTX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -29.41, BRTX is not doing good in the industry: 88.32% of the companies in the same industry are doing better.
There is no outstanding debt for BRTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -29.41 |
ROIC/WACCN/A
WACC8.75%
2.3 Liquidity
BRTX has a Current Ratio of 2.07. This indicates that BRTX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of BRTX (2.07) is worse than 74.20% of its industry peers.
BRTX has a Quick Ratio of 2.07. This indicates that BRTX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of BRTX (2.07) is worse than 72.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.07 | ||
| Quick Ratio | 2.07 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 37.85% over the past year.
BRTX shows a strong growth in Revenue. In the last year, the Revenue has grown by 249.02%.
Measured over the past years, BRTX shows a very strong growth in Revenue. The Revenue has been growing by 25.27% on average per year.
EPS 1Y (TTM)37.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40%
Revenue 1Y (TTM)249.02%
Revenue growth 3Y100.17%
Revenue growth 5Y25.27%
Sales Q2Q%240.45%
3.2 Future
BRTX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 48.29% yearly.
The Revenue is expected to grow by 207.13% on average over the next years. This is a very strong growth
EPS Next Y-38.45%
EPS Next 2Y3.28%
EPS Next 3Y39.42%
EPS Next 5Y48.29%
Revenue Next Year57%
Revenue Next 2Y54.95%
Revenue Next 3Y286.04%
Revenue Next 5Y207.13%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
BRTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BRTX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as BRTX's earnings are expected to grow with 39.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.28%
EPS Next 3Y39.42%
5. Dividend
5.1 Amount
BRTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:BRTX (11/10/2025, 8:00:02 PM)
After market: 1.5382 +0.16 (+11.46%)1.38
+0.01 (+0.73%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners8.77%
Inst Owner Change17.56%
Ins Owners24.02%
Ins Owner Change0%
Market Cap11.95M
Revenue(TTM)605.20K
Net Income(TTM)-10.72M
Analysts82.5
Price Target8.16 (491.3%)
Short Float %1.86%
Short Ratio1.63
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-35.23%
Min EPS beat(2)-93.06%
Max EPS beat(2)22.6%
EPS beat(4)3
Avg EPS beat(4)6.92%
Min EPS beat(4)-93.06%
Max EPS beat(4)69.45%
EPS beat(8)7
Avg EPS beat(8)12.9%
EPS beat(12)10
Avg EPS beat(12)12.72%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-53.09%
Min Revenue beat(2)-93.55%
Max Revenue beat(2)-12.63%
Revenue beat(4)0
Avg Revenue beat(4)-57.92%
Min Revenue beat(4)-93.55%
Max Revenue beat(4)-12.63%
Revenue beat(8)4
Avg Revenue beat(8)50.41%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-38.46%
EPS NQ rev (1m)0%
EPS NQ rev (3m)10%
EPS NY rev (1m)0%
EPS NY rev (3m)1.25%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)12.2%
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.04%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 19.75 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.47 | ||
| P/tB | 2.8 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.27
EYN/A
EPS(NY)-1.09
Fwd EYN/A
FCF(TTM)-1.11
FCFYN/A
OCF(TTM)-1.1
OCFYN/A
SpS0.07
BVpS0.56
TBVpS0.49
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -125.92% | ||
| ROE | -221.32% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 94.53% | ||
| FCFM | N/A |
ROA(3y)-89.42%
ROA(5y)-144.93%
ROE(3y)-108.73%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.07
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 52.81% | ||
| Cap/Sales | 17.73% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.07 | ||
| Quick Ratio | 2.07 | ||
| Altman-Z | -29.41 |
F-Score4
WACC8.75%
ROIC/WACCN/A
Cap/Depr(3y)175.34%
Cap/Depr(5y)N/A
Cap/Sales(3y)170.15%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40%
EPS Next Y-38.45%
EPS Next 2Y3.28%
EPS Next 3Y39.42%
EPS Next 5Y48.29%
Revenue 1Y (TTM)249.02%
Revenue growth 3Y100.17%
Revenue growth 5Y25.27%
Sales Q2Q%240.45%
Revenue Next Year57%
Revenue Next 2Y54.95%
Revenue Next 3Y286.04%
Revenue Next 5Y207.13%
EBIT growth 1Y-1.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-46.46%
OCF growth 3YN/A
OCF growth 5YN/A
BIORESTORATIVE THERAPIES INC / BRTX FAQ
Can you provide the ChartMill fundamental rating for BIORESTORATIVE THERAPIES INC?
ChartMill assigns a fundamental rating of 4 / 10 to BRTX.
Can you provide the valuation status for BIORESTORATIVE THERAPIES INC?
ChartMill assigns a valuation rating of 1 / 10 to BIORESTORATIVE THERAPIES INC (BRTX). This can be considered as Overvalued.
What is the profitability of BRTX stock?
BIORESTORATIVE THERAPIES INC (BRTX) has a profitability rating of 1 / 10.
Can you provide the expected EPS growth for BRTX stock?
The Earnings per Share (EPS) of BIORESTORATIVE THERAPIES INC (BRTX) is expected to decline by -38.45% in the next year.